Scancell Interim Earnings Report

Scancell EPS Results

• Actual EPS: -GBX 1.35
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Scancell Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Scancell Announcement Details

• Quarter: Interim
• Date: 1/30/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Scancell (LON:SCLP) (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma. The precise patient population that iSCIB1+ brings benefit to, in combination with CPIs, has been identified, enabling precision-biomarker led registrational development. The lead Moditope® peptide active immunotherapy, Modi-1, is being investigated in a Phase 2 study in a broad range of solid tumours and also has shown encouraging interim clinical data. Scancell’s wholly-owned subsidiary, Glymab Therapeutics Ltd., has been established with the intention to develop an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab A/S.